Health-related Quality of Life in the Phase III LUME-Colon 1 Study

Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. The different...

Descripción completa

Detalles Bibliográficos
Autores: Lenz, Heinz Joseph, Argilés Martínez, Guillem|||0000-0002-1487-7108, Yoshino, Takayuki|||0000-0002-0489-4756, Lonardi, Sara|||0000-0002-7593-8138, Falcone, Alfredo, Limón, María Luisa|||0000-0003-4409-3029, Sobrero, Alberto, Hastedt, Claudia, Peil, Barbara, Voss, Florian, Griebsch, Ingolf, Van Cutsem, Eric|||0000-0002-6372-1230
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:223620
Acceso en línea:https://ddd.uab.cat/record/223620
https://dx.doi.org/urn:doi:10.1016/j.clcc.2019.08.005
Access Level:acceso abierto
Palabra clave:HRQoL
MMRM
Nintedanib
QoL
Time to deterioration
Descripción
Sumario:Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. The different analyses consistently showed that patients' overall global health status/quality of life status was not impaired by active treatment with nintedanib versus placebo, and that patients perceived some benefits with nintedanib compared with placebo.

Similares en LA Referencia